Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 5
2006 4
2007 1
2008 1
2009 2
2010 1
2011 1
2012 1
2013 3
2014 2
2015 1
2016 2
2017 2
2018 2
2019 10
2020 6
2021 9
2022 11
2023 9
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Bladder cancer invasion along a tension-free vaginal mesh.
Ochi A, Harada S, Fukuokaya W, Honma K, Huang T, Abe H. Ochi A, et al. Among authors: abe h. IJU Case Rep. 2021 Jan 21;4(2):104-107. doi: 10.1002/iju5.12254. eCollection 2021 Mar. IJU Case Rep. 2021. PMID: 33718818 Free PMC article.
Decreased tacrolimus concentration due to Campylobacter colitis.
Akanuma T, Ochi A, Inoue T, Okada D, Abe H, Kuji H, Suzuki T. Akanuma T, et al. Among authors: abe h. Saudi J Kidney Dis Transpl. 2019 Nov-Dec;30(6):1490-1491. doi: 10.4103/1319-2442.275501. Saudi J Kidney Dis Transpl. 2019. PMID: 31929304 No abstract available.
Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma.
Fukuokaya W, Yanagisawa T, Hashimoto M, Yamamoto S, Koike Y, Imai Y, Iwatani K, Onuma H, Ito K, Urabe F, Tsuzuki S, Kimura S, Miki J, Oyama Y, Abe H, Kimura T. Fukuokaya W, et al. Among authors: abe h. Cancer Immunol Immunother. 2023 Apr;72(4):841-849. doi: 10.1007/s00262-022-03291-5. Epub 2022 Sep 14. Cancer Immunol Immunother. 2023. PMID: 36102985 Free PMC article.
Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors.
Fukuokaya W, Kimura T, Komura K, Uchimoto T, Nishimura K, Yanagisawa T, Imai Y, Iwatani K, Ito K, Urabe F, Tsuzuki S, Kimura S, Terada N, Mukai S, Oyama Y, Abe H, Kamoto T, Azuma H, Miki J, Egawa S. Fukuokaya W, et al. Among authors: abe h. Urol Oncol. 2022 Jul;40(7):346.e1-346.e8. doi: 10.1016/j.urolonc.2022.02.020. Epub 2022 Mar 26. Urol Oncol. 2022. PMID: 35346571
Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma.
Fukuokaya W, Kimura T, Yanagisawa T, Kimura S, Tsuzuki S, Koike Y, Iwamoto Y, Enei Y, Tanaka M, Urabe F, Onuma H, Honda M, Miki J, Oyama Y, Abe H, Egawa S. Fukuokaya W, et al. Among authors: abe h. Cancer Immunol Immunother. 2022 Jan;71(1):229-236. doi: 10.1007/s00262-021-02980-x. Epub 2021 Jun 8. Cancer Immunol Immunother. 2022. PMID: 34100985 Free PMC article.
67 results